Welcoming by Design Pilot: Reducing Structural Stigma by Changing Clinic Systems and Architectural Design

Welcoming by Design Pilot: Reducing Structural Stigma by Changing Clinic Systems and Architectural Design to Make HIV Clinics More Friendly, Private, and Patient-Centric

The purpose of this study is to test the feasibility and acceptability of implementing clinic system changes and physical structures in Uganda to improve aesthetics, welcome, and privacy to reduce HIV stigma, improve retention-in-care, and improve the patient experience.

To evaluate pilot/implementation outcomes, the outcomes of fidelity, feasibility, and acceptability will be assessed prior to intervention. After the changes are done to two HIV interventions clinics, the outcome surveys will assess if the changes were disruptive or impeded the workings of the clinics.

Study Overview

• Status: Withdrawn
• Conditions: Hiv
• Intervention / Treatment: Other: Clinics remodeling

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Minneapolis, Minnesota, United States, 55414
      • University of Minnesota

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults 18 and older
• Enrolled in the HIV clinics where we are working
• Able to independently consent for interview, survey, or focus group.

Exclusion Criteria:

• Unable to provide consent
• Does not speak English or Luganda (local language around Kampala and Entebbe)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Interventions clinics to be remodeled	Other: Clinics remodeling; changes to the clinics will be planned based on baseline surveys

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acceptability survey	How well an intervention will be received by the target population and the extent to which the intervention meets the needs of the target population and organizational setting. This will be assessed through qualitative evaluation and a quantitative survey from patients and staff.	Baseline
Feasibility	An assessment of the practicality of a proposed idea or project, by assessing recruitment capacity, and ability to complete proposed modifications in clinics. The intervention will be judged feasible if enrollment and metrics can be completed.	baseline
Fidelity to the Intervention	Assesses whether the intervention was delivered as intended, using the intervention plan/checklist	6-months post intervention
Outcomes survey	assesses if the changes were disruptive or impeded the workings of the clinics.	6-months post intervention

Collaborators and Investigators

• Sponsor: University of Minnesota

Study record dates

Study Major Dates

• Study Start (Actual): July 30, 2024
• Primary Completion (Estimated): July 30, 2027
• Study Completion (Estimated): July 30, 2027

Study Registration Dates

• First Submitted: November 8, 2022
• First Submitted That Met QC Criteria: November 29, 2022
• First Posted (Actual): December 8, 2022

Study Record Updates

• Last Update Posted (Estimated): September 11, 2025
• Last Update Submitted That Met QC Criteria: September 4, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Blood-Borne Infections; Urogenital Diseases; Genital Diseases; Immune System Diseases; Infections; RNA Virus Infections; Virus Diseases; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Slow Virus Diseases; HIV Infections; Acquired Immunodeficiency Syndrome
• Other Study ID Numbers: MED-2023-32453'

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No